Edotreotide
SomaKit TOC (edotreotide) is a small molecule pharmaceutical. Edotreotide was first approved as Somakit toc on 2016-12-08. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. It is known to target somatostatin receptor type 2.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ga-68-dotatoc | New Drug Application | 2019-09-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 5 | 11 | 4 | — | 8 | 26 |
| Pituitary neoplasms | D010911 | — | — | 1 | — | 1 | 2 | ||
| Glioma | D005910 | EFO_0000520 | — | 1 | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 3 | 5 | — | — | 2 | 8 | |
| Carcinoid tumor | D002276 | D3A.00 | 3 | 5 | — | — | 2 | 8 | |
| Medulloblastoma | D008527 | 1 | 4 | — | — | 2 | 6 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | 2 | 2 | — | — | 2 | 6 |
| Paraganglioma | D010235 | 1 | 2 | — | — | 2 | 4 | ||
| Pheochromocytoma | D010673 | 1 | 1 | — | — | 1 | 3 | ||
| Insulinoma | D007340 | — | 1 | — | — | 1 | 2 | ||
| Vipoma | D003969 | — | 1 | — | — | 1 | 2 | ||
| Gastrinoma | D015408 | — | 1 | — | — | 1 | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | 2 | — | — | — | — | 2 | ||
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 2 | — | — | — | — | 2 |
| Von hippel-lindau disease | D006623 | Q85.83 | 1 | — | — | — | — | 1 | |
| Multiple endocrine neoplasia type 1 | D018761 | E31.21 | 1 | — | — | — | — | 1 | |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Lymphoma | D008223 | C85.9 | 1 | — | — | — | — | 1 | |
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Paraneoplastic syndromes | D010257 | 1 | — | — | — | — | 1 | ||
| Gastro-enteropancreatic neuroendocrine tumor | C535650 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | — | — | — | — | 1 | 1 | |
| Small cell lung carcinoma | D055752 | — | — | — | — | 1 | 1 | ||
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | — | — | — | — | 1 | 1 |
| Ganglioneuroma | D005729 | — | — | — | — | 1 | 1 | ||
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | — | — | 1 | 1 | |
| Glucagonoma | D005935 | — | — | — | — | 1 | 1 | ||
| Myocarditis | D009205 | I51.4 | — | — | — | — | 1 | 1 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | 1 | 1 | |
| Gliosarcoma | D018316 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EDOTREOTIDE |
| INN | edotreotide |
| Description | Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.
|
| Classification | Small molecule |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 204318-14-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408350 |
| ChEBI ID | — |
| PubChem CID | 158782 |
| DrugBank | DB15494 |
| UNII ID | U194AS08HZ (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 246 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more